IFRX
InflaRx N.V.·Healthcare
2.60
5.109%(−0.14)
Market OpenLast Updated: — ET
52W L: $0.7152W H: $2.95
IFRX NEWS
seekingalpha.com
May 8
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
marketbeat.com
May 8
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Get InflaRx alerts:Sign UpIzicopan positioned as a next-generation C5aR inhibitor Riedemann described izicopan as an oral agent designed to block the C5a receptor, a pathway he called a “critical driver of inflammatory cascade.
globenewswire.com
May 8
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses.
globenewswire.com
May 6
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share.
globenewswire.com
May 6
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it intends to develop izicopan, an oral C5a receptor (C5aR) inhibitor with potential best-in-class properties, in AAV, a life-threatening kidney disorder. InflaRx is conducting Phase 2 planning for izicopan in AAV and is evaluating the feasibility of multiple development approaches, including the potential for an expedited path to the commercial market, in an effort to best address the evolving regulatory environment surrounding the currently approved comparator, avacopan.
globenewswire.com
May 4
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new pre-clinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reactive metabolite formation is widely used in drug development as an early mechanistic indicator of potential bioactivation-related safety risk.
